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Background: Antimicrobial resistance has emerged as a major threat to global public health. Thus, the surveillance
of changes in antimicrobial resistance in local and global settings is a paramount necessity. While many studies
have tracked antimicrobial resistance, only a small percentage surveyed ocular isolates. The purpose of this study
was to report the in vitro susceptibility of bacterial pathogens isolated from ocular samples in New York, NY from
2010 to 2015.
Methods: A retrospective review of ocular isolates was conducted. All organisms were collected by 25 separate
inpatient wards and outpatient clinics, and were analyzed by the clinical microbiology laboratory at Mount Sinai
Hospital. Clinical Laboratory and Standards Institute (CLSI) guidelines were followed for susceptibility testing and
breakpoint interpretations.
Results: A total of 549 bacterial organisms were isolated from 1664 cultures (33%) during the 6-year study period.
Of these, 358 isolates (65.2%) underwent susceptibility testing. 182 (50.8%) isolates were Gram-positive. The most
common Gram-positive bacterium was Staphylococcus aureus (62.1%). Methicillin-resistance decreased in S. aureus
isolates (31.3% in 2010, 14.1% in 2015) but was without significant change (p = 0.25). When analyzing all S. aureus
isolates recovered during the study period, there were significantly more methicillin-resistant S. aureus (MRSA)
isolates resistant to fluoroquinolones (p <0.0001), erythromycin (p <0.0001), and trimethoprim/sulfamethoxazole
(TMP/SMZ; p <0.05). Overall, Streptococcus pneumoniae isolates showed reduced susceptibility to erythromycin,
but were otherwise susceptible to the other antimicrobials tested. Haemophilus influenzae (26.1%) and Pseudomonas
aeruginosa (23.9%) were the most common Gram-negative bacteria isolated. Resistance to ampicillin and TMP/SMZ
was observed in several of the H. influenzae isolates. P. aeruginosa isolates did not show high resistance overall,
however, it was noted that isolates resistant to meropenem were also resistant to other antimicrobials (p < 0.01).
Conclusion: Overall, antimicrobial resistance was infrequent for the Gram-negative and Gram-positive bacteria
analyzed. While the MRSA isolates demonstrated increased resistance to multiple antimicrobial classes, this is
expected for this pathogen. Due to the continued use of broad-spectrum oral and systemic antimicrobials to
treat ocular infections, findings of this study and other surveillance studies specific to ocular isolates should be
used as resources in effective decision making in the treatment of ocular disease.
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Antimicrobial resistance is an issue that has been impact-
ing medicine for many years. Whether in primary care or
specialized care settings, antimicrobial resistance has been
on the rise and has affected the way healthcare providers
treat bacterial infections. Particularly in ophthalmic
settings, physicians tend to treat ocular infections by
prescribing empiric antibiotics because they often do
not have data from culture analysis. As a result, there
is a lack of awareness of fluctuating trends in antimicro-
bial resistance of many common pathogens [1–4]. This is
an important concern, especially due to the fact that many
ocular pathogens, if shown to possess multi-drug resist-
ance (MDR), i.e. non-susceptibility to at least one agent in
three or more antimicrobial classes [5], can be difficult to
treat, which increases the chances of severe ocular damage
and vision loss [3, 6, 7].
Generally, broad-spectrum antibiotics are used to treat
many ocular infections, including microbial keratitis,
conjunctivitis, and endophthalmitis; however, the patho-
genic organisms that cause these conditions have shown
increased resistance to antibiotics over the past decade.
For example, Staphylococcus species and Pseudomonas
aeruginosa have demonstrated resistance to fluoroquino-
lones, macrolides, and β-lactams [2, 3, 6, 8]. Haemophilus
influenzae, a common Gram-negative bacterium, has also
shown increased resistance to trimethoprim [9–12].
There have been a few nationwide surveillance stud-
ies, such as Ocular TRUST and ARMOR, which have
tracked resistance patterns in many common ocular
pathogens [9, 13]. However, given the growing import-
ance of this issue, there is also a need for smaller,
regional studies to obtain local data. Many such
single-center studies have been surveying and tracking
antimicrobial resistance in order to establish effective
treatment methods against ocular infections on a local
level [6, 14–19]. The goal of this retrospective study
was to determine resistance patterns in ocular pathogens
isolated and analyzed by the Mount Sinai Hospital clin-
ical microbiology laboratory in New York, NY and con-
tribute our findings to the growing knowledge base
regarding antimicrobial resistance of ocular pathogens.
In turn, these findings can also help influence intelli-
gent and effective antibiotic use in the New York City
metropolitan area, with the potential to help develop
informed treatment protocols against common ocular
pathogens.Methods
A retrospective, consecutive data review study was
conducted. The study was approved by the institu-
tional review board of Mount Sinai Hospital and the
tenets of the Declaration of Helsinki were followed.Collection of ocular isolates
A total of 1664 ocular cultures were performed from
over 25 separate inpatient wards and outpatient clinics
over a 6-year period (January 2010 to December 2015).
The clinical microbiology laboratory at Mount Sinai
Hospital performed all cultures and antimicrobial sus-
ceptibility testing for these facilities. For the purposes of
this review, only specimens that tested positive for a
bacterial organism were included in the study. Fungal
isolates were not analyzed.
Eye culture workup and organism identification
Eye culture specimens (swabs of various ocular anatomic
sites, corneal scrapings, and vitreous/aqueous fluids)
were either directly plated to agar at the time of collec-
tion or sent to the clinical microbiology laboratory for
plating. The routine culture media used for eye cultures
included blood agar, chocolate agar, and CDC anaerobe
5% sheep blood agar. Providers collecting specimens at
the bedside would also frequently add a thioglycollate
broth during collection. All media was incubated aerob-
ically in a 5% CO2 environment or under anaerobic con-
ditions at 35–37 °C per laboratory standard operating
protocols. Positive cultures were determined by the
laboratory’s standard operating protocol. For specimens
that were directly plated (isolated from corneal scrapings
or vitreous fluids), the organism had to be localized to
the area of the plate where the specimen was planted.
For those specimens collected with a swab, the organism
had to be localized in the first quadrant (first streak
area) of the plate. If growth was observed in the 2nd, 3rd,
or 4th area, consultation with the microbiology director
typically resulted in the organism being labeled as a
contaminant.
Significant ocular pathogens were primarily identified
using routine biochemical testing and the VITEK-2
instrument (bioMérieux, Inc., Durham, NC). If the
VITEK-2 result failed, alternate identification systems
used by the laboratory included API strips (bioMérieux,
Inc., Durham, NC) and the rapID identification system
(Remel, Lenexa, KS).
Susceptibility testing
All susceptibility testing was performed in the Mount
Sinai Hospital clinical microbiology laboratory. A total
of 358 isolates underwent susceptibility testing from a
total of 549 isolated bacterial isolates. Only significant
ocular pathogens as defined by the laboratory standard
operating protocol underwent susceptibility testing.
Organisms identified that were believed to be contaminants
or normal flora (i.e. Coagulase-negative Staphylococcus and
Corynebacterium species) were excluded from analysis
since susceptibility testing was not performed. This in-
cluded 152 coagulase-negative Staphylococcus (CoNS)
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Providers always had the opportunity to call the laboratory
and request susceptibility testing on these isolates if they
deemed them significant. The panel of antimicrobials
tested was determined by the microbiology director and
antimicrobial stewardship based on the institution’s
antibiotic formulary. The primary susceptibility testing
method used in the laboratory during the study was
VITEK-2 (bioMérieux, Inc., Durham, NC), which was per-
formed per manufacturer’s recommendations. Streptococcus
species, infrequently isolated, and fastidious organisms were
tested by E-test (bioMérieux Inc., Durham, NC) per manu-
facturer’s recommendations. Interpretations (susceptible,
intermediate, susceptible dose-dependent, or resistant) were
determined using Clinical Laboratories and Standards
Institute (CLSI) guidelines (M100 [20] or M45 [21] docu-
ments) relevant to the year the organism was tested.
Data organization & inclusion procedures
All data was collected from the Laboratory Information
System used by the Mount Sinai Hospital clinical
microbiology laboratory. The data was imported into a
Microsoft Excel spreadsheet file and all important patient
identifiers were properly and securely discarded in accord-
ance with IRB guidelines. The data imported included date
of collection, age of patient, ward, collection site, organism
isolated and MIC values against a variety of antibiotics.
Only isolates that underwent susceptibility testing were
included in this study. Susceptibility profiles are shown for
microbial species that were tested at least 30 times during
the study period with the exception of MRSA (n = 28),
though not all antimicrobials were tested against each iso-
late. MIC50 and MIC90 values were also calculated.
Statistical analysis
Statistical analysis was conducted using the program Prism
(software version 7.0a; GraphPad software). A Fisher’s exact
test was used to study the prevalence of methicillin-
resistance amongst all Staphylococcus aureus isolates
during the study period as well as to compare differences
in resistance between methicillin-resistant Staphylococcus
aureus (MRSA) and methicillin-susceptible Staphylococcus
aureus (MSSA) isolates. Comparisons amongst S. aureus
and age of infection were conducted using a Chi-Squared
test. Statistical significance was defined as p < 0.05.
Results
Of a total of 1664 cultures performed during the study
period, 549 bacterial organisms were isolated. Of these,
358 ocular pathogens (65.2%) underwent susceptibility
testing, which included 113 S. aureus, 30 S. pneumoniae,
42 P. aeruginosa, & 46H. influenzae isolates (Table 1).
Of the 358 isolates, 41 (11.5%), 30 (8.4%), 11 (3.1%), 17
(4.7%), and 3 (0.8%) samples were isolated from theconjunctiva, cornea, eyelid, contact lens, and vitreous
fluid respectively. The remaining 256 (71.5%) samples
were collected from unspecified ocular sites. Gram-positive
bacteria accounted for 50.8% of the total isolates. S. aureus
was the most common Gram-positive bacterium [113 of
182 (62.1%)] while H. influenzae was the most common
Gram-negative bacterium [46 of 176 (26.1%)]. Comparison
by patient age, in years, (Table 2) shows that the amount of
Gram-positive organisms (S. aureus, coagulase-negative
Staphylococcus (CoNS), and S. pneumoniae isolates) was
higher in the elderly group (>65 years) than in any other
group and increased in an age-dependent manner. MRSA
infections were statistically more likely to occur in the two
oldest age groups, i.e. >40 years, when compared to the
younger age groups (p < 0.05). Gram-negative organisms,
with the exception of H. influenzae, were more prevalent in
the middle-aged groups, i.e. 18–64 years. Interestingly, H.
influenzae isolates were more prevalent in the youngest
and oldest age groups, presenting a bimodal distribution.
Staphylococcus aureus
MRSA
Over the 6-year period that was evaluated, the prevalence
of methicillin-resistant S. aureus showed a decreasing yet
statistically insignificant trend (Fig. 1), with 31.30% resist-
ance in 2010 compared to 14.30% resistance in isolates
collected in 2015 (p = .25).
A total of 28 cultures tested positive for methicillin-
resistant S. aureus (Table 3a). MRSA isolates exhibited high
resistance against erythromycin (89.29%), clindamycin
(35.7%), levofloxacin (50%), and ciprofloxacin (80%)
and high susceptibility to the remainder of the antimi-
crobials tested. No MRSA isolates showed resistance to
vancomycin, daptomycin or linezolid.
MSSA
A total of 85 cultures tested positive for methicillin-
susceptible S. aureus (Table 3a). MSSA isolates exhibited
high susceptibility to the majority of antimicrobials tested
with the exception of clindamycin (34.12%) and erythro-
mycin (44.05%). No isolates were found to be resistant to
vancomycin, daptomycin, gentamicin, or linezolid. Unlike
MRSA, MSSA isolates were highly susceptible to levoflox-
acin and ciprofloxacin.
Resistance in MRSA and MSSA was also compared
(Fig. 2). As expected, the resistance observed against
ciprofloxacin (p <0.0001), erythromycin (p <0.0001),
levofloxacin (p <0.0001), and TMP/SMZ (p <0.05) was
significantly higher for the MRSA isolates compared to
the MSSA isolates. This increased resistance is also
seen in the MIC50/MIC90 values, in which MRSA had
equal or higher MIC50/MIC90 values than MSSA in re-
sponse to ciprofloxacin, erythromycin, levofloxacin,
and TMP/SMZ.
Table 1 Ocular Isolates Collected & Analyzed at Mount Sinai Hospital (2010–2015)
Gram-Positive Organisms No. %Gram-Positive %Total Gram-Negative Organisms No. %Gram-Negative %Total
Staphylococcus aureus Non-Fermenting Gram-Negative Bacilli
MSSA 85 46.70% 23.74% Pseudomonas aeruginosa 42 23.86% 11.73%
MRSA 28 15.38% 7.82% Stenotrophomonas maltophilia 7 3.98% 1.96%
CoNS Achromobacter xylosoxidans 6 3.41% 1.68%
Staphylococcus epidermidis 13 7.14% 3.63% Moraxella catarrhalis 4 2.27% 1.12%
Staphylococcus haemolyticus 2 1.10% 0.56% Acinetobacter baumannii 3 1.70% 0.84%
Staphylococcus warneri 2 1.10% 0.56% Pseudomonas luteola 1 0.57% 0.28%
Staphylococcus capitis 1 0.55% 0.28% Pseudomonas putida 1 0.57% 0.28%
Unspecified CoNS 2 1.10% 0.56% Pseudomonas (Flavimonas) oryzihabitans 1 0.57% 0.28%
Other Unspecified Acinetobacter spp. 1 0.57% 0.28%
Streptococcus pneumoniae 30 16.48% 8.38% Moraxella lacunata 1 0.57% 0.28%
Corynebacterium pseudodiphthericum 3 1.65% 0.84% Unspecified Moraxella spp. 1 0.57% 0.28%
Streptococcus pyogenes (Group A) 2 1.10% 0.56% Achromobacter (Alcaligenes) denitrificans 1 0.57% 0.28%
Streptococcus intermedius 2 1.10% 0.56% Chryseobacterium indologenes 1 0.57% 0.28%
Unspecified Corynebacterium spp. 2 1.10% 0.56% Elizabethkingia meningoseptica 1 0.57% 0.28%
Bacillus cereus 2 1.10% 0.56% Enterobacteriaceae
Streptococcus anginosus 1 0.55% 0.28% Serratia marcescens 18 10.23% 5.03%
Streptococcus mitis 1 0.55% 0.28% Escherichia coli 10 5.68% 2.79%
Enterococcus faecium 1 0.55% 0.28% Klebsiella oxytoca 7 3.98% 1.96%
Enterococcus faecalis 1 0.55% 0.28% Klebsiella pneumoniae 5 2.84% 1.40%
Corynebacterium (CDC Group G) 1 0.55% 0.28% Enterobacter cloacae 2 1.14% 0.56%
Gemella morbillorum 1 0.55% 0.28% Citrobacter koseri 2 1.14% 0.56%
Unspecified Bacillus spp. 1 0.55% 0.28% Pantoea agglomerans 2 1.14% 0.56%
Aerococcus viridans 1 0.55% 0.28% Raoultella ornithinolytica 1 0.57% 0.28%
Citrobacter freundii 1 0.57% 0.28%
Providencia rettgeri 1 0.57% 0.28%
Morganella morganii 1 0.57% 0.28%
Proteus mirabilis 1 0.57% 0.28%
Other
Haemophilus influenzae 46 26.14% 12.85%
Haemophilus parainfluenzae 2 1.14% 0.56%
Aggregatibacter aphrophilus 2 1.14% 0.56%
Eikenella corrodens 2 1.14% 0.56%
Neisseria meningitidis 1 0.57% 0.28%
Pasteurella multocida 1 0.57% 0.28%
Bolded organisms are commonly observed bacterial pathogens
Bolded and underlined terms represent important classes of microorganisms
Abbreviation: MSSA methicillin-susceptible S. aureus, MRSA methicillin-resistant S. aureus, CoNS coagulase-negative Staphylococcus, spp. species
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A total of 30 cultures tested positive for S. pneumoniae
(Table 3b). Overall, S. pneumoniae isolates exhibited rela-
tively low resistance to all of the antimicrobials tested
against them. This is further supported by the low MIC50
and MIC90 values for these antimicrobials. Only erythro-
mycin showed moderate resistance, in which five of the iso-
lates (16.67%) were resistant, as well as a large MIC rangefrom .016 to 32 ug/ml. Vancomycin, clindamycin, and levo-
floxacin remained effective against S. pneumoniae, with
each antimicrobial generating over 93% susceptibility.Pseudomonas aeruginosa
A total of 42 cultures tested positive for P. aeruginosa
(Table 4a). The majority of antimicrobials were greater
Table 2 Frequency of ocular pathogens by age group
Microorganism Age Distribution (years)
≤2 3–17 18–39 40–64 ≥65
N (%) N (%) N (%) N (%) N (%)
MSSA 14 (16.5%) 8 (9.4%) 15 (18.8%) 18 (21.2%) 30 (35.3%)
MRSA 2 (7.1%) 2 (7.1%) 2 (7.1%) 11 (39.3%) 11 (39.3%)
CoNS 2 (10.0%) 1 (5.0%) 1 (5.0%) 6 (30.0%) 10 (50.0%)
Streptococcus pneumoniae 5 (16.7%) 2 (6.7%) 2 (6.7%) 12 (40.0%) 9 (30.0%)
Pseudomonas aeruginosa 1 (2.4%) 3 (7.1%) 12 (28.6%) 17 (40.5%) 9 (21.4%)
Haemophilus influenzae 14 (30.4%) 5 (10.9%) 3 (6.5%) 12 (26.1%) 12 (26.1%)
Klebsiella spp. 4 (33.3%) 0 (0%) 3 (25%) 2 (16.7%) 3 (25%)
Serratia marcescens 1 (5.6%) 1 (5.6%) 8 (44.4%) 6 (33.3%) 2 (11.1%)
Abbreviations: MSSA = methicillin-susceptible Staphylococcus aureus, MRSA = methicillin-resistant Staphylococcus aureus, CoNS = coagulase-negative Staphylococcus,
spp = species
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ception of both meropenem and piperacillin/tazobac-
tam (11.91 and 12.20% resistance respectively). The
five isolates that were resistant to meropenem were
more likely to be resistant to other classes of antimi-
crobials (p = 0.008), including aminoglycosides and
fluoroquinolones.Haemophilus influenzae
A total of 46 cultures tested positive for H. influenzae
(Table 4b). The vast majority of isolates were suscep-
tible to most of the antimicrobials tested with the
exception of TMP/SMZ and ampicillin, both of which
showed high MIC90 values. All isolates were tested
against TMP/SMZ, with 17 (37%) isolates showing resist-
ance. Of the 33 isolates tested against ampicillin, 10
(30.30%) were resistant.Fig. 1 Prevalence of MRSA from 2010–2015. An overall decreasing
trend in MRSA prevalence is observed from 2010–2015. However,
the trend is not statistically significant (p = 0.25).Discussion
In this retrospective review, 358 microorganisms were
analyzed by a single-center institution over a 6-year
study period. A wide variety of Gram-positive and Gram-
negative organisms were collected including CoNS, S.
marcescens, K. oxytoca, and E. coli, as well as more com-
mon bacterial pathogens such as S. aureus, S. pneumoniae,
H. influenzae, and P. aeruginosa. In this study the number
of Gram-negative organisms (49.2%) was nearly equal to
the number of Gram-positive organisms (50.8%). While
other single-center studies have found a much higher pro-
portion of Gram-positive organisms in collected samples
[1, 7, 18, 22–24], this study exhibited a nearly equivalent
Gram-positive to Gram-negative ratio. This difference is
likely due to the clinical microbiology laboratory protocols
that did not require susceptibility testing of CoNS until
mid-2015 from eye sources due to the likelihood of these
isolates being contaminants. Specifically, there were an
additional 152 CoNS isolates, the majority isolated from
conjunctival swabs, which did not undergo susceptibility
testing. If these isolates had undergone susceptibility test-
ing, the distribution between Gram-positive and Gram-
negative bacteria would change considerably (65.5 and
34.5% respectively) and be more in line with previously
published studies.
This study also showed an uneven distribution of ocular
isolates among age groups. Gram-positive organisms were
most common in the elderly, while Gram-negative
organisms, except H. influenzae, were most common
in the middle age ranges. H. influenzae isolates had a
bimodal distribution, being more common in the
youngest and oldest age groups. Additionally MRSA
was statistically more likely (p < 0.05) to be found in
the two oldest age groups (40–64 years and >65 years)
when compared to the younger age groups suggesting
a higher possibility of MRSA infection with increasing
Table 3 Susceptibility profiles for selected Gram-positive species, S. aureus (a) and S. pneumoniae (b)
3a: Susceptibility Profile for 113 S. aureus isolates
Antimicrobial MIC (ug/mL) Interpretation N (%)
Organism Range MIC50 MIC90 Susceptible Intermediate Resistant
Clindamycin MRSA 0.25 – ≥8 0.25 ≥8 18 (64.3) 0 (0) 10 (35.7)
MSSA ≤0.12 – ≥8 0.25 <0.5 56 (65.9) 0 (0) 29 (34.1)
Ciprofloxacin* MRSA ≤0.5 – ≥8 ≥8 ≥8 5 (20) 0 (0) 20 (80)
MSSA ≤0.5 – ≥8 ≤0.5 ≤0.5 74 (91.4) 1 (1.2) 6 (7.4)
Daptomycin MRSA 0.25 – 1 0.5 1 28 (100) 0 (0) 0 (0)
MSSA ≤0.12 – 1 0.25 0.5 85 (100) 0 (0) 0 (0)
Erythromycin MRSA ≤0.25 – ≥8 ≥8 ≥8 3 (10.7) 0 (0) 25 (89.3)
MSSA ≤0.25 – ≥8 0.5 ≥8 47 (56) 0 (0) 37 (44)
Gentamicin MRSA ≤0.5 – ≥16 ≤0.5 8 24 (85.7) 2 (7.1) 2 (7.1)
MSSA ≤0.5 – 4 ≤0.5 ≤0.5 85 (100) 0 (0) 0 (0)
Levofloxacin MRSA 0.25 – ≥8 4 ≥8 6 (21.4) 8 (28.6) 14 (50)
MSSA ≤0.12 – ≥8 0.25 2 80 (94.1) 2 (2.4) 3 (3.5)
Linezolid MRSA 2 – 4 2 2 28 (100) 0 (0) 0 (0)
MSSA 1 – 4 2 2 85 (100) 0 (0) 0 (0)
Trimethoprim/Sulfamethoxazole MRSA ≤0.5 – ≥16 ≤0.5 8 25 (89.3) 0 (0) 3 (10.7)
MSSA ≤0.5 – ≥16 0.5 0.5 84 (98.8) 0 (0) 1 (1.2)
Tetracycline* MRSA ≤1 – ≥16 ≤1 4 22 (91.7) 0 (0) 2 (8.3)
MSSA ≤1 – ≥16 ≤1 4 48 (94.1) 0 (0) 3 (5.9)
Vancomycin MRSA ≤0.5 – 2 1 2 28 (100) 0 (0) 0 (0)
MSSA ≤0.5 – 2 1 1 37 (100) 0 (0) 0 (0)
3b: Susceptibility Profile for 30 S. pneumoniae isolates
Antimicrobial MIC (ug/mL) Interpretation N (%)
Range MIC50 MIC90 Susceptible Intermediate Resistant
Ceftriaxone (non-meningitis)# .004 – 0.5 0.032 0.25 23 (100) 0 (0) 0 (0)
Clindamycin# .032 – 1 0.125 0.25 27(93.2) 1 (3.4) 1 (3.4)
Erythromycin .016 – 32 0.25 2 22 (73.3) 3 (10) 5 (16.7)
Levofloxacin 0.25 – 4 1 1 29 (96.7) 0 (0) 1 (3.3)
Penicillin (non-meningitis)# .008 – 2 0.032 0.5 25 (100) 0 (0) 0 (0)
Vancomycin .25 – 2 0.5 1 29 (96.7) 0 (0) 1 (3.3)
*Antimicrobials that were not tested against all 28 MRSA isolates
#Antimicrobials that were not tested against 30 or more S. pneumoniae isolates
Abbreviations: MSSA = methicillin-susceptible Staphylococcus aureus, MRSA = methicillin-resistant Staphylococcus aureus, MIC = minimum inhibitory
concentration (at 50% and 90%)
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remains unclear, it may be due to the underdeveloped
immune system common in infants and children as
well as the depressed immune function observed in the
elderly, making the risk of microbial infection in these
groups higher [25].
Several drugs are used to treat ocular infections, each
with a different mechanism of action. Despite this, many
of the pathogens observed in this study are adapting in
ways that lead to increased resistance to several classesof antibiotics. Fluoroquinolones, which are a class of
drugs often used as first-line treatment for ocular infec-
tions, have generally been successful, especially as newer
generations have been introduced [1, 22]. However, just
like other antimicrobial classes, the systemic use of these
fluoroquinolones as first-line broad-spectrum antibiotics
tends to lead to increases in resistance due to selective
pressure [4, 15, 16, 19]. In this study, 50 and 80% of
MRSA isolates showed resistance to levofloxacin and
ciprofloxacin respectively, while 3.53 and 7.41% of
Fig. 2 Antimicrobial Resistance Observed in MRSA & MSSA Isolates.
Significant differences in antimicrobial resistance between MRSA &
MSSA isolates were observed for ciprofloxacin, erythromycin, levofloxacin,
and TMP/SMZ. Note: Daptomycin, vancomycin, and linezolid are not
included because no resistance was shown for either MRSA or MSSA
isolates. Abbreviations: MSSA=methicillin-susceptible Staphylococcus
aureus; MRSA =methicillin-resistant Staphylococcus aureus; TMP/SMZ =
trimethoprim/sulfamethoxazole; **** = (p< .0001); * = (p< .05)
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ciprofloxacin, respectively.
Multi-drug resistance (MDR) was observed in many
of the MRSA isolates collected in this study (n = 12;
42.9%). When compared to MSSA isolates, MRSA
isolates have shown statistically significant increases
in MDR when compared to MSSA isolates, making
them resilient pathogens. However, even with this
increased resistance, S. aureus isolates have shown
limited to no resistance to vancomycin, daptomycin
or linezolid, making these treatments reliably effective
in bacterial populations that have already shown high
resistance to fluoroquinolones, aminoglycosides, and
macrolides.
Fluctuating trends in the prevalence of MRSA strains
have been reported. Some studies have presented in-
creasing trends in MRSA over extended periods of time
[23, 24], while others, including those presented by the
CDC, state a decline in MRSA prevalence [26–28]. This
study shows a non-statistically significant, decreasing
trend over the 6-year study period suggesting that
MRSA prevalence has not fluctuated drastically over the
last several years. While it is unclear why MRSA preva-
lence has remained relatively stable in our review, it may
result from successful infection control strategies in both
hospitals and surrounding communities, or perhaps the
cyclical replacement of dominant, infective MRSA
strains by MSSA strains over time [27].In contrast to MRSA, resistance among S. pneumoniae
and P. aeruginosa isolates was low against the antimicro-
bials tested while resistance among H. influenzae isolates
was evident primarily against ampicillin and TMP/SMZ.
Overall these three organisms did not show alarming re-
sistance to the antimicrobials tested and are consistent
with other antimicrobial surveillance studies that have
been conducted recently [1, 7, 13, 19].
Several factors are important in the development of
antimicrobial resistance in ocular isolates. Overuse of
antibiotics is one of the main causes [16]. Other causes
include use of an antibiotic when it is not warranted, as
in the case of a viral infection, or improper use, such as
stopping a course of antibiotics early or using them
prophylactically [17]. Since most ocular infections are
often resolved through topical application rather than
through systemic use, the inherent pharmacokinetic dif-
ferences between the two must be taken into account
when evaluating antimicrobial resistance [29, 30]. Given
the high risk of permanent vision loss with eye infection,
such as corneal ulcers and endopthalmitis, topical antibi-
otics tend to be at higher concentrations and are often
used as prophylaxis despite limited evidence on their
efficacy. The role that topical antibiotics play in anti-
microbial resistance is still ambiguous due to the lack of
research in this specific area as well as the lack of stan-
dardized ocular tissue-specific breakpoints. With the
lack of these breakpoints to qualify resistance, CLSI
breakpoints have been agreed upon by many researchers
as useful indicators of resistance in topical antibiotics
and even with the differences mentioned, similar resist-
ance trends are observed in both topical and systemic
antibiotic use [31, 32]. Additionally, since systemic
antibiotics are still used to treat chronic ocular infec-
tions, in such usage, CLSI breakpoints are appropri-
ate. In fact, systemic use of antibiotics may be the
key cause of resistance in all isolates, regardless of
the source of infection [33, 34]. However, the uncer-
tainty of the role of topical antibiotics is still apparent
and therefore requires further attention in order to
fully delineate their role.
Limitations of this study include the retrospective
nature of this study, which predetermined our sample
size, ultimately limiting our analysis of all possible
antimicrobial resistance trends. Because there was no
standardized protocol for collection of isolates, inevit-
ably there was a large variation in the culturing pro-
cedure among physicians. This lack of uniformity
may have affected organism recovery in culture. Add-
itionally, the antimicrobial panel underwent small
fluctuations from year to year leading to slightly in-
consistent susceptibility testing and excluded testing
on more recently introduced fluoroquinolones, such
as gatifloxacin.
Table 4 Susceptibility profiles of selected Gram-negative species, P. aeruginosa (a) and H. influenzae (b)
4a: Susceptibility Profile for 42 P. aeruginosa isolates
Antimicrobial MIC (ug/mL) Interpretation N (%)
Range MIC50 MIC90 Susceptible Intermediate Resistant
Amikacin ≤2 – <16 ≤2 16 42 (100) 0 (0) 0 (0)
Ceftazidime ≤1 – 8 4 8 42 (100) 0 (0) 0 (0)
Ciprofloxacin ≤0.25 – ≥4 ≤0.25 1 41 (97.6) 0 (0) 1 (2.4)
Cefepime ≤1 – 8 2 <8 42 (100) 0 (0) 0 (0)
Gentamicin ≤1 – ≥16 ≤1 4 41 (97.6) 0 (0) 1 (2.4)
Imipenem ≤1 – ≥16 2 4 38 (90.5) 1 (2.4) 3 (7.1)
Levofloxacin ≤0.12 – ≥ 8 1 2 41 (97.6) 0 (0) 1 (2.4)
Meropenem 0.125 – >32 1 8 35 (83.3) 2 (4.8) 5 (11.9)
Piperacillin/Tazobactam ≤4 – ≥128 8 ≥128 36 (87.8) 0 (0) 5 (12.2)
Tobramycin* ≤1 – <4 ≤1 <4 18 (100) 0 (0) 0 (0)
4b: Susceptibility Profile for 46 H. influenzae isolates
Antimicrobial MIC (ug/mL) Interpretation N (%)
Range MIC50 MIC90 Susceptible Intermediate Resistant
Ampicillin 0.25 – >256 0.5 >256 22 (66.7) 1 (3) 10 (30.3)
Amoxicillin/Clavulanate 0.5 – 8 1 4 41 (95.3) 0 (0) 2 (4.7)
Ceftriaxone .004 – 32 0.016 0.125 42 (97.7) 0 (0) 1 (2.3)
Ciprofloxacin* .008 – 1 0.032 0.5 27 (100) 0 (0) 0 (0)
Levofloxacin .008 – 2 0.064 0.5 30 (100) 0 (0) 0 (0)
Trimethoprim/Sulfamethoxazole 0.032 – >32 0.5 >32 23 (50) 6 (13) 17 (36.9)
*Antimicrobials that that weren’t tested against 30 or more P. aeruginosa and H. influenzae isolates
Abbreviation: MIC = minimum inhibitory concentration (50 and 90%)
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This 6-year retrospective study reported the numbers of
common ocular bacterial isolates and their susceptibility
profiles. The study demonstrated a relatively even ratio
of Gram-negative to Gram-positive organisms and a vari-
able distribution amongst age groups, depending on the
organism. This study also found increased resistance to
other drugs among MRSA strains when compared to
MSSA strains, as well as moderately low resistance in
Gram-negative organisms. Future studies should include a
panel of commonly used antimicrobials for ocular in-
fections, including more recently introduced fluoroqui-
nolones. To prevent further progression of resistance,
findings of this study and other surveillance data on
ocular isolates should be used as resources in effective
decision making in the treatment of ocular disease and
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